Lilly migraine drug wins European panel thumbs-up

A European Medicines Agency panel on Friday recommended the approval of U.S. pharmaceutical group Eli Lilly's migraine treatment, bringing the drug one step closer to being sold in the European Union.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.